Ars pharmaceuticals, inc.SPRY.US Overview
US StockHealthcare
(No presentation for SPRY)
SPRY Overall Performance
SPRY AI Analysis & Strategy
SPRY Recent Performance
2.15%
Ars pharmaceuticals, inc.
0.81%
Avg of Sector
-1.14%
S&P500
SPRY PowerScanner
SPRY Key Information
SPRY Valuation Metrics
SPRY Earnings Table
SPRY Profile
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.